Shanghai Fosun Pharma (Group) Co., Ltd. released its financial report for the third quarter of 2024. The report shows that in the third quarter of 2024, the company's revenue reached 10.449 billion yuan, a year-on-year increase of 12.30%; the net profit attributable to shareholders of the listed company was 0.786 billion yuan, a significant year-on-year increase of 55.43%; the net profit after deducting non-recurring gains and losses was 0.582 billion yuan, a year-on-year increase of 474.77%; the net cash flow generated from operating activities was 1.08 billion yuan, a year-on-year increase of 65.68%. The basic earnings per share was 0.29 yuan, a year-on-year increase of 52.63%. During the reporting period, the total assets of the company were 115.265 billion yuan, an...Show More

Shanghai Fosun Pharma (Group) Co., Ltd. released its financial report for the third quarter of 2024. The report shows that in the third quarter of 2024, the company's revenue reached 10.449 billion yuan, a year-on-year increase of 12.30%; the net profit attributable to shareholders of the listed company was 0.786 billion yuan, a significant year-on-year increase of 55.43%; the net profit after deducting non-recurring gains and losses was 0.582 billion yuan, a year-on-year increase of 474.77%; the net cash flow generated from operating activities was 1.08 billion yuan, a year-on-year increase of 65.68%. The basic earnings per share was 0.29 yuan, a year-on-year increase of 52.63%. During the reporting period, the total assets of the company were 115.265 billion yuan, an increase of 1.58% compared to the end of the previous year; the owner's equity attributable to shareholders of the listed company was 47.301 billion yuan, an increase of 3.54% compared to the end of the previous year. The board of directors of the company guarantees the truthfulness, accuracy, and completeness of the quarterly report, with no false records, misleading statements, or major omissions. The report was released by Chairman Wu Yifang on October 29, 2024.